RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class antibody-drug conjugate (ADC), at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago. The study focuses on the efficacy and safety of RC88 in treating advanced solid […]